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mann*† 
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ABSTRACT: Pterin-containing natural products have diverse functions in life but an efficient and easy scheme for their in 
vitro synthesis is not available. Here, we report a chemo-enzymatic 14-step, one-pot synthesis that can be used to generate 13C- and 
15N-labeled dihydrofolates (H2F) from glucose, guanine and p-aminobenzoyl-L-glutamic acid. This synthesis stands out from previ-
ous approaches to produce H2F in that the average yield of each step is >91% and it requires only one single purification step. The 
use of a one-pot reaction allowed us to overcome potential problems with individual steps during the synthesis. The availa-
bility of labeled dihydrofolates allowed the measurement of heavy atom isotope effects for the reactions catalyzed by the drug 
target dihydrofolate reductase and established that protonation at the N5 position of H2F and hydride transfer to the C4 position 
occur in a stepwise mechanism. This chemo-enzymatic pterin synthesis can be applied to the efficient production of other fo-
lates and a range of other natural compounds with applications in nutritional, medical and cell biological research. 
INTRODUCTION 
Pterin is a common motif found in natural products. Fo-
late, the essential vitamin that fuels the one carbon cycle for 
the biosynthesis of nucleotide and amino acid building 
blocks, was one of first natural products found to contain 
pterin.1, 2 The metabolic importance of pterins is illustrated 
by their integration into enzyme cofactors such as molyb-
dopterin and tetrahydrobiopterin.3-5 Pterin natural prod-
ucts are also used as pigments in the butterflies Catopsilia 
argante and Appias nero,6 whereas biopterin-α-glucoside 
serves as a natural sunscreen that protects cellular contents 
from photo-induced damages in photosynthetic cyanobac-
teria.7  
5,6,7,8-Tetrahydrofolic acid (H4F), which in addition to 
the pterin ring system contains p-aminobenzoic acid 
(pABA) and L-glutamic acid (Glu), is required for the bio-
synthesis of metabolites that are key for cell survival and 
replication.2 A one-carbon unit in different oxidation states 
can be added to the N5 and/or N10 position of H4F and used 
to produce metabolites such as thymidylate, purines, gly-
cine, serine and S-adenosylmethionine (SAM) (Figure 1).8 
Given the central importance of folate biochemistry for cell 
replication and survival, dihydrofolate reductase (DHFR), 
thymidylate synthase (TS) and serine hydroxymethyltrans-
ferase (SHMT) have long been exploited as important drug 
targets in the treatment of bacterial infections,9 malaria10, 11 
and cancer,12, 13 and the DHFR-targeting drugs trime-
thoprim, proguanil, pyrimethamine and methotrexate are 
listed as essential medicines by the World Health Organiza-
tion (WHO).14 Nevertheless, as with many clinically used 
drugs, resistance to antifolates has begun to emerge15-17 and 
the investigation of the enzymes of the one-carbon cycle is 
an important part of inhibitor design strategies.18 
Detailed mechanistic insight into enzyme-catalyzed reac-
tions is often obtained by isotopic labeling and measure-
ment of kinetic isotope effects (KIE)19-22 or spectroscopic 
analysis.23,24 Information derived from regio- and stereo-
specific substrate labeling has been used to design inhibi-
tors with dissociation constants in the micro- to picomolar 
range.25 However, the use of these techniques to investigate 
folate dependent enzymes is hindered by the absence of a 
general and efficient method to specifically label atoms of 
the pterin ring system, particularly at the N5, C6, C7 and C9 
positions, which are directly linked to the chemistry of the 
catalyzed reactions. Folate and its derivatives can be syn-
thesized by connecting the pterin, pABA and glutamate 
groups in sequential order,26 and several synthetic strate-
gies to incorporate an isotopic label into pterin in a regio-
specific manner have been reported.27-30 Pterins have been 
synthesized by condensing guanidine or dihydroxyacetone 
with the respective heterocyclic starting materials, and N5, 
C2 and C6 labeled folates have been made previously.27, 28 
However, because symmetric reagents are used in these 
syntheses, regio-selective isotope labeling of C7 and C9 po-
sitions cannot easily be achieved.28, 30 In all cases, the yields 
of labeled folate or derivatives are low (<5% overall yield) 
and the procedures depend on multiple purification steps. 
Chemo-enzymatic strategies have also been described,31-33 
whereby H4F was condensed with 11C-formaldehyde or 14C-
formic acid to yield the corresponding isotopically labeled 
[11C]-5,10-methylene-H4F, [14C]-5-formyl-H4F and [14C]-10-
formyl-H4F. However, a general and efficient method to la-
bel the pterin ring in folates has never been developed. 
 
  
Figure 1. Folate coenzymes in one-carbon metabolism. Folic acid is converted to 7,8-dihydrofolic acid (H2F) and 5,6,7,8-tetrahydro-
folic acid (H4F). One-carbon units attached to H4F are highlighted. 1: dihydrofolate reductase (DHFR); 2: 10-formyl-H4F synthetase 
(FTHFS); 3: 10-formyl-H4F dehydrogenase (FDH); 4: 5,10-methenyl-H4F cyclohydrolase (MTHFC); 5: 5,10-methylene-H4F dehydro-
genase (MTHFD); 6: 5,10-methylene-H4F reductase (MTHFR); 7: methionine synthase (MS); 8: serine hydroxymethyltransferase 
(SHMT); 9: thymidylate synthase (TS); 10: 5,10-methenyl-H4F synthetase (MTHFS); 11: 5-formimino-H4F cyclodeaminase (FTCD); 
S-adenosylmethionine (SAM). 
In nature, the pterin ring in folate is formed from guano-
sine triphosphate (GTP) in one biochemical step catalyzed 
by GTP cyclohydrolase (GTP-CH),34, 35 an enzyme found in 
all kingdoms of life ranging from archaebacteria, insects and 
plants to humans. In all GTP-CH-catalyzed reactions, GTP is 
converted to a pterin via a set of tandem reactions that have 
no equivalent in organic chemistry. GTP cyclohydrolase I 
(GTP-CH-I) catalyzes the formation of 7,8-dihydroneopterin 
triphosphate (DHNTP) from GTP by mediating four distinct 
chemical reactions (Figure S1): hydrolysis of the purine ring 
yielding a N-formyl intermediate, N-deformylation, a stere-
ospecific Amadori rearrangement of the ribose moiety and 
ring closure to form the pterin.36-38 Because no symmetric 
reagent is used in this reaction, GTP-CH-I can be used to 
synthesize the pterin ring system of folate with heavy iso-
topes incorporated regio- and stereo-selectively.39 It is 
therefore surprising that GTP-CH-I has not been used in any 
in vitro enzymatic pathway to synthesize folates. Perhaps, 
the low catalytic turnover (kcat = 0.05 s-1)40 and the rather 
low stability of the product 7,8-dihyropterin41 toward oxy-
gen and light have limited the use of GTP-CH-I in synthesis. 
Here we report a 14-step one-pot chemo-enzymatic syn-
thesis of 7,8-dihydrofolic acid (H2F) that exploits the well-
established procedures to isotopically label GTP39, 42, 43 by 
using GTP-CH-I to site-specifically isotope label pterins. The 
low enzymatic activity and product instability of GTP-CH-I 
were addressed by enzymatic coupling. Using our method-
ology, H2F enriched with stable isotopes at the N5 and C6 
positions could be synthesized efficiently in pure form in 
>30% yield from isotopically enriched D-glucose and gua-
nine. Given the high degree of purity and isotopic enrich-
ment (>97%, supplementary information), heavy-atom 
KIEs could be measured to investigate the mechanism of the 
E. coli DHFR (EcDHFR) catalyzed reduction of H2F to H4F. 
 
RESULTS AND DISCUSSION 
In vitro synthesis of folate 
 The biosynthetic pathway to folate in E. coli uses the 
building blocks D-glucose, guanine and p-aminobenzoyl-L-
glutamate (pABA-Glu). In the biosynthetic scheme of H2F 
(Figure 2), the C2, C3 and C4 positions of glucose corre-
spond to the C7, C6 and C9 positions of H2F and N1, C2, N3, 
C4, C5, C6, N7 and N9 of guanine correspond to N3, C2, N1, 
C4b, C4a, C4, N5 and N8 in H2F. GTP is the key intermediate 
in this synthetic pathway, connecting the purine salvage 
pathway to de novo folate biosynthesis. Accordingly, a min-
imum of 14 enzymes need to be assembled in vitro to pro-
duce H2F. 
The GTP biosynthetic pathway is composed of enzymes 
from the pentose phosphate and purine salvage pathways 
(Figure 2 and S2). D-Glucose serves as the starting material, 
which is transformed into phosphoribose pyrophosphate 
(PRPP) in five steps that are catalyzed by hexokinase (HK), 
glucose 6-phosphate dehydrogenase (G6PDH), 6-phos-
phogluconate dehydrogenase (6PGDH), phosphoriboiso-
merase (PRI) and ribose-phosphate pyrophosphokinase 
(phosphoribosylpyrophosphate synthetase; PRS).44 PRPP is 
then combined with guanine to form GMP under xanthine 
guanine phosphoribosyl transferase (XGPRT) catalysis. The 
resulting GMP is converted to the corresponding nucleotide 
triphosphate, in reactions catalyzed by guanylate kinase 
(GK) and pyruvate kinase (PK). Since HK and GK use ATP as 
the phosphate source, PK can also function as the recycling 
enzyme. On the other hand, PRS uses ATP as the pyrophos-
phate source and so myokinase (MK) was included to regen-
erate ATP from AMP.45 A significant amount of NADP+ is also 
needed for GTP biosynthesis. Hence, the recently developed 
glutathione reductase (GR)/glutaredoxin 2 (GRX2) recy-
cling system was used for the regeneration of the oxidized 
cofactor.44 The GR/GRX2 system uses disulfides like 2-hy-
droxyethyl disulfide (HED or oxidized β-mercaptoethanol) 
or cystine as regenerating reagents and produces thiols as 
useful byproducts, which protect the enzymes and interme-
diates from oxidative damage. 
The conversion of GTP to DHNTP by GTP-CH-I marks the 
entry point of the folate de novo pathway. It has been re-
ported that potassium and magnesium ions are positive al-
losteric effectors that can increase the rate of the GTP-CH-I 
reaction up to 5-fold.46 The addition of these cations, how-
ever, was insufficient, as the reaction was found to be in-
complete giving a poor yield of DHNTP (Figure 3a). In folate 
de novo biosynthesis, dephosphorylation of DHNTP to 7,8-
dihydroneopterin monophosphate (DHNMP) by DHNTP py-
rophosphohydrolase (DHNTPase) is the biochemical step 
followed by the GTP-CH-I reaction (Figure 2).47, 48 Knockout 
of the DHNTPase gene significantly impairs folate metabo-
lism in E. coli,48 which suggests that DHNTP phosphohydrol-
ysis is a key regulatory step in folate metabolism. In other 
words, the activity of GTP-CH-I is most likely inhibited by its 
own product, DHNTP, which therefore needs to be immedi-
ately converted to DHNMP in order to sustain the activity of 
GTP-CH-I. In the presence of DHNTPase, GTP-CH-I showed 
a marked rate enhancement (Figure S3), with near com-
plete conversion of GTP and a high yield of DHNMP (Figure 
3b). 
 
Figure 2. Strategy for the synthesis of 7,8-dihydrofolate (H2F). 
Guanosine triphosphate (GTP) was made via the pentose phos-
phate and purine salvage pathways under hexokinase (HK), 
glucose 6-phosphate dehydrogenase (G6PDH), 6-phosphoglu-
conate dehydrogenase (6PGDH), phosphoriboisomerase (PRI), 
ribose-phosphate pyrophosphokinase (PRS), xanthine guanine 
phosphoribosyl transferase (XGPRT), guanylate kinase (GK) 
and pyruvate kinase (PK) catalysis. In the folate de novo path-
way, GTP is converted to 7,8-dihydroneopterin (DHN), cata-
lyzed by GTP cyclohydrolase I (GTP-CH-I), 7,8-dihydro-
neopterin pyrophosphatase (DHNTPase) and alkaline phos-
phatase (ALP); DHN is then converted to H2F, catalyzed by di-
hydroneopterin aldolase (DHNA), 6-hydroxymethyl 7,8-dihy-
dropterin pyrophosphokinase (HPPK) and dihydropteroate 
synthase (DHPS). The additional enzymes myokinase (MK), 
glutathione reductase (GR) and glutaredoxin 2 (GRX2) are used 
for the regeneration of ATP and NADP+.44, 45 The pterin atoms 
of H2F derived from glucose (red) and guanine (blue) are high-
lighted. Details for each biosynthetic step are described in Fig-
ure S2. 
  
Figure 3. Conversion of guanosine triphosphate (GTP) into 7,8-
dihydroneopterin triphosphate (DHNTP) and monophosphate 
(DHNMP). Anion exchange chromatographic analyses of GTP 
incubated for 2 h at 37 °C with (a) GTP cyclohydrolase I (GTP-
CH-I) which shows partial conversion to DHNTP, and (b) both 
GTP-CH-I and 7,8-dihydroneopterin triphosphate pyrophos-
phohydrolase (DHNTPase) for essentially complete conversion 
to DHNMP. Production of guanosine diphosphate (GDP) is most 
likely due to the non-enzymatic hydrolysis of GTP during incu-
bation. 
Additional enzymes are needed to convert DHNMP into 
folate. To the best of our knowledge, the natural enzyme re-
sponsible for the conversion of DHNMP to 7,8-dihydro-
neopterin (DHN) is unknown37, 48 and alkaline phosphatase 
(ALP) was used instead as a surrogate. DHN is subjected to 
a retro-aldol reaction catalyzed by dihydroneopterin al-
dolase (DHNA) to yield 6-hydroxymethyl-7,8-dihydropterin 
(HMDP),49, 50 which then reacts with ATP in the presence of 
6-hydroxymethyl 7,8-dihydropterin pyrophosphokinase 
(HPPK) (Figure 4).51 In E. coli, the resulting intermediate 6-
hydroxymethyl-7,8-dihydropterin pyrophosphate 
(HMDPpp) is first condensed with pABA and then with glu-
tamate, catalyzed by dihydropteroate synthase (DHPS)52 
and dihydrofolate synthase (DHFS)53 respectively, to finally 
generate dihydrofolate (H2F). However, DHPS accepts pre-
assembled pABA-Glu as a substrate,54 so DHFS is not re-
quired in the in vitro reaction. The entire H2F synthetic path-
way only requires one purification step of the product, but 
ALP needs to be removed by ultrafiltration prior to the ad-
dition of DHNA, HPPK and DHPS as the phosphatase can 
also catalyze the phosphorolysis of ATP and HMDPpp. Two 
additional modifications were made to further improve the 
overall yield. A N2-filled glove box system was used, because 
all reduced pterin-containing compounds, DHNTP, DHNMP, 
DHN, HMDP, HMDPpp and the final product H2F, are oxy-
gen-sensitive.41 Also, cystine was found to be the preferred  
 
Figure 4. Conversion of 7,8-dihydroneopterin (DHN) to dihy-
drofolate (H2F). Dihydroneopterin aldolase (DHNA) catalyzes 
the transformation of DHN to 6-hydroxymethyl-7,8-dihydrop-
terin (HMDP), which is pyrophosphorylated by 6-hydroxyme-
thyl 7,8-dihydropterin pyrophosphokinase (HPPK). The result-
ing 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
(HMDPpp) is converted to H2F by dihydropteroate synthase 
(DHPS), whose promiscuity allows the use of pre-assembled 
pABA-Glu as substrate and the omission of dihydrofolate syn-
thase (DHFS) in the in vitro synthetic pathway. 
reagent over HED for the NADP+ regeneration system oper-
ated by GR and GRX2. Perhaps, β-mercaptoethanol made 
from the reduction of HED interferes with other enzymatic 
reactions, such as the chelation of Zn2+ in GTP-CH-I. The to-
tal turnover numbers for the regeneration of ATP from ADP 
by pyruvate kinase or of ATP from AMP by pyruvate ki-
nase/myokinase are both ~100,55 while the total turnover 
number for our GR/GRX2-based NADP+ recycling system 
can reach 5 x 105.44 In general, a typical biosynthetic cascade 
produced 6.6 mg of H2F from 9 mg of glucose with an overall 
yield of 30%, i.e. the yield of each chemical transformation 
is in excess of 91%. 
 
Synthesis of selectively labeled folate 
Five isotopically labeled H2Fs were synthesized using the 
newly developed in vitro pathway (Figure 5a). Liquid chro-
matography-high-resolution mass spectrometry (LC-
HRMS) analysis of [6-13C]-H2F, produced from [3-13C]-D-glu-
cose, showed an increase of ~1 amu; 13C-NMR spectroscopy 
revealed a singlet peak at 152 ppm. Additionally, long-range 
coupling between 6-13C and protons on C7 and C9 of [6-13C]-
H2F were observed in the 1H,13C-HMBC spectrum (Figure 
5b). 
To incorporate a 15N label into the pterin moiety at N5, [7-
15N]-guanine was used. The resulting product showed ~1 
amu increase in LC-HRMS analysis and a 15N signal at 285 
ppm coupling to C7 and C9 protons in the 1H,15N-HMBC 
spectrum (Figure 5c). 
When [3-13C]-D-glucose and [7-15N]-guanine were com-
bined to produce [5-15N][6-13C]-H2F, a mass increase of ~2 
 amu was measured. The 13C-NMR spectrum showed a dou-
blet at 152 ppm with a coupling constant 1JCN of 7.5 Hz; long 
range coupling between the protons on C7 and C9 was ob-
served in the 1H,13C-HMBC and 1H,15N-HMBC spectra (Sup-
plementary Information) indicating that both the N5 and C6 
positions of H2F were isotopically enriched. 
 
Figure 5. H2Fs labeled with stable isotopes on the pterin ring system. (a) Patterns of isotopic distribution are determined by the 
starting material isotopic enrichment used during H2F biosynthetic assembly. (b) 1H,13C-HMBC and (c) 1H,15N-HMBC of [6-13C]-H2F 
and [5-15N]-H2F. Protons attached to C7 (3.95 ppm) and C9 (3.87 ppm) correlate to C6 (152 ppm) or N5 (285 ppm). 1H-NMR spectra 
of all compounds and additional 2D-NMR characterization of [5-15N][6-13C]-H2F, [6,7,9-13C3]-H2F and [5-15N][6,7,9-13C3]-H2F are re-
ported in Figures S12-S15. For HRMS data of all compounds see Table S3 and Figures S16-S21. Isotopic enrichment was calculated 
to be at least 97% from the mass spectrometric data (illustrated in Figures S22-24). 
Similarly, [6,7,9-13C3]-H2F and [5-15N][6,7,9-13C3]-H2F were 
synthesized from 13C6-D-glucose and [7-15N]-guanine, and 
their identity confirmed by HRMS and NMR spectroscopy 
(Supporting Information). 
 
Heavy-atom kinetic isotope effects on the reaction cat-
alyzed by EcDHFR 
The preparation of 13C- and 15N-labeled dihydrofolates al-
lowed the measurement of heavy atom isotope effects for 
the reactions catalyzed by dihydrofolate reductase (DHFR), 
a key enzyme in the one-carbon metabolism and validated 
target for the treatment of bacterial infections, malaria and 
cancer.56 DHFR catalyzes the reduction of H2F to H4F via 
transfer of the pro-R hydride from C4 of NADPH to the Re-
face on C-6 accompanied with protonation of N5 of H2F (Fig-
ure 6).57, 58 Several aspects of the reaction mechanism war-
rant additional investigation. In particular, the transition 
state structure and the order of chemical transformation 
events have not been fully determined.59, 60 The active site 
of DHFR provides a favorable environment for N5 protona-
tion by elevating the pKa from 2.6 to 6.5 and using an active 
site water as the proton source.61, 62 Solvent and hydrogen 
 KIE measurements combined with site-directed mutagene-
sis have suggested a stepwise mechanism, in which proto-
nation precedes hydride transfer.63, 64 However, D2O in-
creases the viscosity of the reaction buffer relative to H2O65, 
66 and site-directed modification can alter the catalytic be-
havior of an enzyme67 and additional mechanistic investiga-
tions are needed to establish the order of events. Since iso-
topic substitution does not alter the chemistry of the reac-
tion but only the kinetics, [6-13C]-H2F and [5-15N]-H2F were 
used to measure the 15N- and 13C-heavy atom kinetic isotope 
effects. Pre-steady-state kinetic measurements at 15 °C, by 
fluorescence resonance energy transfer from the active site 
tryptophan in DHFR to the reduced cofactor, yield first-or-
der hydride transfer rate constants with an accuracy up to 
0.7% (Figure S25-27, Table S4). While a 13C-KIE of 1.015 ± 
0.006 was observed for the reduction of [6-13C]-H2F, the cor-
responding 15N-KIE for [5-15N]-H2F was essentially unity 
(0.999 ± 0.006) under the same conditions. To confirm this 
finding, [5-15N][6-13C]-H2F was used to probe both positions 
at the same time and the measured value for the corre-
sponding multiple heavy-atom KIE was 1.014 ± 0.008, sta-
tistically identical to that obtained when the substrate was 
labeled with 13C only.  
The observed 15N-KIE on hydride transfer indicates that 
N5 protonation is not isotopically sensitive, likely because 
it is not rate-limiting under pre-steady state conditions (as 
the reaction is essentially irreversible,58 the observed KIE 
will tend to unity rather than to the equilibrium isotope ef-
fect).22 On the other hand, the measured 13C-KIE indicates 
that the hydride transfer step is rate-determining. This 
strongly suggests a stepwise mechanism. If the protonation 
and hydride transfer steps were concerted, 15N- and 13C-la-
beled H2Fs should both yield measurable KIEs;19, 21, 22 this 
interdependency may also lead to an additive effect in the 
multiple heavy-atom isotope effect measurement with the 
double-labeled substrate.19, 21, 22 In other words, our results 
suggest that the pre-steady state kinetic measurement at pH 
7.0 reveals only the step of hydride transfer, because proto-
nation of N5 is in rapid equilibrium and the ensemble of re-
action-ready conformations is mostly populated with pro-
tonated H2F. Importantly, these results confirm the validity 
of previous solvent KIE and site-directed mutagenesis stud-
ies, which also concluded that the sequence of chemical 
events (protonation and hydride transfer) is distinct and 
strictly ordered.64, 68 Overall, the results provided here 
strongly support a mechanism where protonation and hy-




Dihydrofolate was produced enzymatically in an easy 
one-pot, high yielding reaction sequence from glucose, gua-
nine and pABA-Glu that required only a single purification 
step. Potential problems with individual steps during the 
synthesis could be overcome through the use of a one-pot 
reaction. This methodology can be used to generate dihy-
drofolates labeled in specific positions with stable isotopes 
with average overall yields of >30%, facilitating many appli-
cations in cell biology and mechanistic enzymology.27-29, 61, 
69, 70 For the first time, heavy-atom KIEs for the DHFR-
catalyzed reduction of H2F could be measured to provide 
strong support for a stepwise reduction of the substrate, in 
which protonation at N5 and hydride transfer from C4 of the 
NADPH to C6 of protonated dihydrofolate proceed inde-
pendently. This chemo-enzymatic pterin synthesis can be 
integrated into other enzymatic procedures to generate fo-
late derivatives31, 32 and other high-value natural products 
that are not easily accessible by conventional synthesis.71 It 
can be applied to nutritional, medical and cell biological re-
search to address questions of in vivo bioavailability and to 





Figure 6. Reduction of 7,8-dihydrofolate (H2F) to 5,6,7,8-tetra-
hydrofolate (H4F) catalyzed by dihydrofolate reductase 
(DHFR). 
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